Intrathecal pump refills at home or at the hospital
| ISRCTN | ISRCTN18031921 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN18031921 |
| Sponsor | Vrije Universiteit Brussel |
| Funder | Fonds Wetenschappelijk Onderzoek |
- Submission date
- 18/11/2025
- Registration date
- 18/11/2025
- Last edited
- 19/11/2025
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not available
Contact information
Prof Maarten Moens
Principal investigator
Principal investigator
Laarbeeklaan 103
Jette
1090
Belgium
| Phone | +32 24775514 |
|---|---|
| stimulusresearchgroup@gmail.com |
Prof Lisa Goudman
Scientific, Public
Scientific, Public
Laarbeeklaan 103
Jette
1090
Belgium
| 0000-0002-2271-9855 | |
| Phone | +32 472412507 |
| lisa.goudman@vub.be |
Study information
| Primary study design | Interventional | |
|---|---|---|
| Allocation | Randomized controlled trial | |
| Masking | Open (masking not used) | |
| Control | Active | |
| Assignment | Crossover | |
| Purpose | Treatment | |
| Scientific title | Intrathecal pump refills at home or at the hospital: a randomized controlled crossover trial | |
| Study acronym | IMPROVE | |
| Study objectives | The IMPROVE study is a randomized, controlled, cross-over trial designed to compare intrathecal pump refills performed at home with those carried out in the hospital. Intrathecal drug delivery (IDD) is used in patients with chronic pain or severe spasticity. Use of IDD requires the performance of pump refills about 4-6 times a year which may be a burdensome and stressful experience for patients and their caregivers. Hospital visits can increase stress, pain, and caregiver strain, while early pilot studies suggest home-based refills may be both safe and more comfortable. | |
| Ethics approval(s) |
Approved 03/09/2025, UZ Brussel/VUB (Laarbeeklaan 101, Jette, 1090, Belgium; +32 24774111; ethiek@uzbrussel.be), ref: 1432025000188 | |
| Health condition(s) or problem(s) studied | Intrathecal pump refill procedures | |
| Intervention | Eighty-two adult patients in Belgium with an implanted intrathecal pump will be enrolled in the IMPROVE study. Each participant will undergo four refill procedures: two at home and two at the hospital, in randomized order. To ensure allocation concealment, the randomization sequence was generated in advance and stored in a secure, access-restricted Excel log. Study duration contains 4 refill procedures for every patient, which entails max. 12 months. | |
| Intervention type | Other | |
| Primary outcome measure(s) |
| |
| Key secondary outcome measure(s) |
| |
| Completion date | 01/10/2028 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 120 Years |
| Sex | All |
| Target sample size at registration | 82 |
| Key inclusion criteria | 1. Actively receiving Intrathecal drug delivery 2. Stable medication dosage for at least 3 months 3. Dutch, French or English speaking adults |
| Key exclusion criteria | 1. Life expectancy < 6 months 2. Patients planned for but not yet received Intrathecal drug delivery implant 3. No residence in Belgium |
| Date of first enrolment | 15/10/2025 |
| Date of final enrolment | 01/10/2027 |
Locations
Countries of recruitment
- Belgium
Study participating centres
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan |
Editorial Notes
19/11/2025: Internal review.
18/11/2025: Trial's existence confirmed by UZ Brussel/VUB.